Background: PHA-022121 (PHA121), an orally bioavailable potent competitive antagonist of the human bradykinin B2 receptor, is being developed for the treatment and prevention of Hereditary Angioedema (HAE) attacks. The gene discussed is BDKRB2; the disease is hereditary angioedema.